ClinicalTrials.gg
CompletedNCT05282797Updated Aug 29, 2023

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test

A Phase 2 interventional study of ANEB-001 and Placebo in Acute Cannabinoid Intoxication, sponsored by Anebulo Pharmaceuticals. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-29.

Sponsored by Anebulo Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The aim of this study is to investigate whether ANEB-001 effectively penetrates the brain and inhibits the psychotropic effects of Δ9-Tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis. This randomized, placebo-controlled, double-blind study is designed as a proof-of-pharmacology and dose finding study for the antagonistic effect of ANEB-001 during a THC challenge. Results of this study will inform the future potential use of ANEB-001 as an emergency treatment for acute cannabinoid intoxication.

Read the detailed description

This study will evaluate whether ANEB-001 effectively inhibits the psychotropic effects of Δ9-Tetrahydrocannabinol (THC). All cohorts in part A and B of the study will be randomized, double-blind and placebo-controlled. Randomization is deemed appropriate to avoid selection bias for active compound or placebo treatment. A double-blind and placebo-controlled design is deemed appropriate because of the safety, tolerability and pharmacodynamic assessments that will be performed in this study. By double-blinding the study, bias arising from study subject's or investigator's knowledge about treatment assignment is avoided. Part C does not include a placebo group and will therefore not be blinded.

02

Conditions studied

  • Acute Cannabinoid Intoxication
03

In context

Lead sponsor

Anebulo Pharmaceuticals is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed prior to any study-mandated procedure
  • between 18 and 30 kg/m2
  • Minimum weight 50 kg
  • Occasional cannabis user

Exclusion criteria

Exclusion Criteria:

  • Evidence of active or chronic condition that could interfere with, or which the treatment of might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator
  • abnormalities, as judged by the investigator
  • Positive surface antigen, antibody or antibody at screening
  • Systolic blood pressure greater than 130 or less than 90 mm Hg and diastolic blood pressure greater than 95 or less than 50 mm Hg at screening Abnormal findings in the resting
  • Use of any medications within 7 days of study drug administration, or less than 5 half-lives (whichever is longer). Exceptions are paracetamol and ibuprofen and topical medications.
  • Use of any vitamin, mineral, herbal and dietary supplements within 7 days of study drug administration, or less than 5 half-lives (whichever is longer)
  • Participation in an drug or device study (last dosing of previous study was within 90 days prior to first dosing of this study)
  • History of abuse of addictive substances (alcohol, illegal substances) or current use of more than 21 units alcohol per week, drug abuse, or regular user of sedatives, hypnotics, tranquilizers, or any other addictive agent other than recreative use of THC
  • Positive test for drugs of abuse (other than THC) at screening.
  • Positive test for drugs of abuse pre-dose
  • Clinically significant suicidal ideation in the past 5 years as judged by the investigator or any life-time suicide attempts
  • History of cannabis-induced psychosis, schizophrenia or other clinically relevant psychiatric disorders, as judged by the investigator.
  • History of a clinically significant mood disorder, including but not limited to major depressive disorder, as judged by the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Part A - ANEB-001

    Subjects receive THC and varying amounts of ANEB-001

    Drug: ANEB-001

  • Placebo comparator
    Part A - Placebo

    Subjects receive THC and placebo

    Drug: Placebo

  • Experimental
    Part B - Cohort 1 - ANEB-001

    Subjects receive 21 mg of THC and 30 mg of ANEB-001

    Drug: ANEB-001

  • Placebo comparator
    Part B - Cohort 1 - Placebo

    Subjects receive 21 mg of THC and placebo

    Drug: Placebo

  • Experimental
    Part B - Cohort 2 - ANEB-001

    Subjects receive 21 mg of THC and 10 mg of ANEB-001

    Drug: ANEB-001

  • Placebo comparator
    Part B - Cohort 2 - Placebo

    Subjects receive 21 mg of THC and placebo

    Drug: Placebo

  • Experimental
    Part B - Cohort 3 - ANEB-001

    Subjects receive 21 mg of THC and 1 hour later, 30 mg ANEB-001

    Drug: ANEB-001

  • Placebo comparator
    Part B - Cohort 3 - Placebo

    Subjects receive 21 mg THC and 1 hour later, placebo

    Drug: Placebo

  • Experimental
    Part B - Cohort 4 - ANEB-001

    Subjects receive 40 mg of THC and 1 hour later, 10 mg of ANEB-001

    Drug: ANEB-001

  • Placebo comparator
    Part B - Cohort 4 - Placebo

    Subjects receive 40 mg of THC and 1 hour later, placebo

    Drug: Placebo

  • Experimental
    Part B - Cohort 5 - ANEB-001

    Subjects receive 30 mg of THC and 1 hour later, 10 mg of ANEB-001

    Drug: ANEB-001

  • Placebo comparator
    Part B - Cohort 5 - Placebo

    Subjects receive 30 mg of THC and 1 hour later, 10 mg of ANEB-001

    Drug: Placebo

  • Experimental
    Part B - Cohort 6 - ANEB-001

    Subjects will consume a high fat meal prior to receiving 30 mg of THC and 1 hour later, 10 mg of ANEB-001

    Drug: ANEB-001

  • Placebo comparator
    Part B - Cohort 6 - Placebo

    Subjects will consume a high fat meal prior to receiving 30 mg of THC and 1 hour later, placebo

    Drug: Placebo

  • Experimental
    Part C - Cohort 7 - ANEB-001

    Subjects receive a 40 mg dose of THC and a 10 mg dose of ANEB-001

    Drug: ANEB-001

  • Experimental
    Part C - Cohort 8 - ANEB-001

    Subjects receive a 60 mg dose of THC and a 20 mg dose of ANEB-001

    Drug: ANEB-001

Interventions

  • Experimental Treatment

  • DrugPlacebo

    Placebo comparator

06

What researchers measure

Primary outcomes

  1. Subjective Feeling High

    Feeling High on a visual analog scale (mm)

    Time frame: Day 1

  2. Postural stability

    Body sway (mm);

    Time frame: Day 1

  3. Subjective Alertness

    Alertness on a visual analog scale (mm)

    Time frame: Day 1

  4. Heart Rate

    Heart Rate in beats/min

    Time frame: Day 1

Secondary outcomes

  1. Subjective Mood

    Mood on a visual analog scale (mm)

    Time frame: Day 1

  2. Subjective Calmness

    Calmness on a visual analog scale (mm)

    Time frame: Day 1

  3. Feeling of Drug Effect

    Feeling of drug effect on a visual analog scale (mm)

    Time frame: Day 1

  4. Symbol Digit Substitution Test (SDST)

    Part C Only

    Time frame: Day 1

  5. Visual Verbal Learning Test (VVLT)

    Part C Only

    Time frame: Day 1

  6. Timed Up-and-Go test (TUG)

    Part C Only

    Time frame: Day 1

  7. Alternate Finger Tapping (AFT)

    Part C Only

    Time frame: Day 1

  8. Basic Symptom Inventory (BSI)

    Part C Only

    Time frame: Day 1

  9. Brief Psychiatric Rating Scale (BPRS)

    Part C Only

    Time frame: Day 1

  10. Clinical Global Impression of Severity (CGIS)

    Part C Only

    Time frame: Day 1

07

Study locations

1 site
  • Centre for Human Drug Research (CHDR)
    Leiden, ZH 2333, Netherlands
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Aug 2023, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2022
First posted
Mar 16, 2022
StartActual
Dec 15, 2021
Primary completionActual
Aug 26, 2023
CompletionActual
Aug 26, 2023
Last update
Aug 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05282797
Lead sponsor
Anebulo Pharmaceuticals
Responsible party
Sponsor
First posted
Mar 16, 2022
Start date
Dec 15, 2021
Primary completion
Aug 26, 2023
Completion
Aug 26, 2023
Last update
Aug 29, 2023

Study contacts

GJ Groeneveld, MD, PhD
principal investigator · CHDR

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selonabant

Start the discussion